echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Johnson & Johnson invests US$780 million in new flu treatment drugs

    Johnson & Johnson invests US$780 million in new flu treatment drugs

    • Last Update: 2021-04-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Compileriver

    When Johnson & Johnson launched the first products of its new crown vaccine in the United States, it was already focusing on the next pandemic.


    A few days ago, Johnson & Johnson subsidiary Janssen will invest US$27 million to purchase Cidara’s leading antiviral conjugate CD388, which can treat and prevent all influenza strains with a single dose.


    The current flu vaccine has several major limitations.


    Cidara is responsible for R&D and production to the second phase.


    Jeffrey Stein said in a conference call with investors on Monday morning that there is still a $753 million R&D budget and milestones waiting for Cidara, as well as "medium to high digit" tiered royalties.


    The Janssen agreement also includes Cidara's another AVC candidate project CD377, which has a slightly shorter duration.


    In addition to the agreement between Cidara and Mundipharma on its main antifungal project Rezafungin in 2019, the biotech company will receive up to US$1.


    Reference source: With one pandemic still raging, J&J bets $780M on a potential flu therapy for the next

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.